current position:Home >> Group Members >> PI >> PI of the Group

Min Lu

Experience

2015.06 - Present  Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Professor)
2009.01 - 2015.06  Ludwig Cancer Research Oxford Branch, Oxford University (Postdoc.)
2007.09 - 2008.10  Beth Israel Deaconess Medical Center, Harvard Medical School (Co-cultured Ph.D.)
1999.09 - 2007.07  Biochemistry Institute, College of Life Science, Zhejiang University (Bachelor, Co-cultured Ph.D.)

Summary of research

He is the obtainer of mutant p53 rescue compounds: 1) revealed novel regulation mechanisms of p53 transactivation activity (Cancer Cell 2013, Cell 2014, Nat Rev Mol Cell Biol 2016); 2) obtained an effective mutant p53 rescue compound and revealed its structural mechanism (Cancer Cell 2021); 3) achieved first-in-human mutant p53 reactivation in human body (Sci Transl Med 2023);3) his compound is recognized as the effective mutant p53 rescue compound (Cancer Cell, 2024).

These findings potentially open a new direction in targeted oncology: targeting tumor suppressors, a cluster of the most prevalently mutated proteins in cancer yet none is drugged. Based on these findings, peers have initialized five p53-targeting clinical trials registered in the ClinicalTrials.gov.


Ten representative Awards/Fund 
2021 NSFC, Key Program, CN
2017 MOST, Youth Principal Investigator, CN
2016 NSFC, Excellent Young Scientist Program, CN
2015 NSFC, Program for Overseas High-Level Experts Introduction, CN
2006 Zhejiang University, ZhuKeZhen Medal, CN
2019 Royal Society of Medicine, Newton Advanced Fellowship, UK
2015 Oxford University, Awards for Excellence, UK
2015 Parliamentary and Scientific Committee, Gave a presentation “Set for Britain” at Parliament, UK
2014 Oxford University, Recognition Scheme, UK
2007 Harvard University, Research Assistant Scholarship, US